{"id":156,"date":"2025-06-03T10:00:00","date_gmt":"2025-06-03T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=156"},"modified":"2025-09-09T07:48:03","modified_gmt":"2025-09-09T07:48:03","slug":"china-original-asset-biontech-and-bms-enters-a-9-1-billion-usd-license-on-pd-1-vegf-bsabs-bnt327-pm8002-from-biotheus","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/156.html","title":{"rendered":"[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-06-02 (June 2, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: BNT327 (PM8002 from Biotheus)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Biopharmaceutical New Technologies (BioNTech)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Bristol Myers Squibb (BMS)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: BsAbs (bispecific antibody)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: targeting PD-L1 and VEGF-A<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: numerous solid tumor types<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: global Phase 3 trials, first-line treatment in extensive stage small cell lung cancer (\u201cES-SCLC\u201d) and non-small cell lung cancer (\u201cNSCLC\u201d)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech and BMS will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech will be eligible to receive:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of&nbsp;$1.5 billion,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">$2 billion total in non-contingent anniversary payments through 2028,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and commercial milestone payments up to $7.6 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Milestone payments up to &nbsp;$4.8 billion <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $11.1 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech and BMS will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits\/losses will be equally shared between BioNTech and BMS.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/news.bms.com\/news\/details\/2025\/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types\/default.aspx\">Bristol Myers Squibb &#8211; BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types (bms.com)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/cninmed.com\/en\/2024\/273.html\">[China BD 2024] Biotheus and BioNTech Enters an Acquisition on PD-L1\/VEGF-A BsAbs PM8002 (BNT327) \u2013 CninMed \u2013 China Innovative Drugs Update<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/cninmed.com\/en\/2023\/271.html\">[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1\/VEGF-A BsAbs PM8002 (BNT327) \u2013 CninMed \u2013 China Innovative Drugs Update<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-06-02 (June 2, 2025) Asset Name: BNT327 (PM8002 from Biotheus) Licensor: Biopharmaceutical New Technologies &hellip; <a title=\"[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/156.html\"><span class=\"screen-reader-text\">[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-156","post","type-post","status-publish","format-standard","hentry","category-china-original-asset"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=156"}],"version-history":[{"count":4,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/156\/revisions"}],"predecessor-version":[{"id":275,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/156\/revisions\/275"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}